Affidea Praha s.r.o.
- Address
- lock Available on a paid plan
Affidea Praha s.r.o. - Cardiovascular and Inflammatory Disease Research
Affidea Praha s.r.o. is a clinical research center specializing in cardiovascular disease prevention and inflammatory musculoskeletal conditions. The center demonstrates expertise in conducting complex, multi-center trials evaluating novel therapeutic interventions for atherosclerotic cardiovascular disease and immune-mediated inflammatory disorders.
- Cardiovascular disease prevention and lipid metabolism disorders, including hypertriglyceridemia and atherosclerosis management
- Long-term safety evaluation of biologic therapies for rheumatologic and dermatologic conditions
- Primary and secondary prevention strategies for major adverse cardiovascular events (MACE)
The center conducts sophisticated studies involving inclisiran and olezarsen for cardiovascular risk reduction, as well as extended follow-up protocols with secukinumab for conditions including psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and chronic plaque psoriasis. Affidea Praha's research portfolio reflects a commitment to advancing therapeutic options for both metabolic cardiovascular risk factors and chronic inflammatory diseases affecting multiple organ systems.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Novartis Pharma AG1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG6trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Affidea Praha s.r.o.
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Pharmacokinetic and Safety Study of Bimekizumab via Different Routes of Administration in Adults with Chronic Cutaneous Inflammation | UCB Biopharma | Phase I | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Secukinumab | 3 | Unknown | 2020-12-22 | 2023-03-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.